Lecture 43

Question 1

_____ is a monoclonal Ab that binds and blocks HER2 (an EGF receptor).

Answer 1

Herceptin

Question 2

_____ is a kinase inhibitor used in the treatment of CML. ONe of the issues with kinase inhibitor use in cancer therapies is that inhibition of the oncogenic driver pathway can induce _____ activation of another pathway that has the same end result, allowing the cancer cells to remain viable. _____ lethality is the term that describes the simultaneous pertubation of two genetic events which results in cellular death.

Answer 2

Imatinib

Feedback activation

Synthetic Lethality

Question 3

Rapamycin and Rapalogs are _____ inhibitors. This is a kinase that normally phosphorylates and activates S6 kinase, which phosphorylates and activates the 40S subunit of Ribosomes. Rapamycin and Rapalogs were very effective in treating some patients with metastatic renal carcinoma, but they did not work at all for other patients with the same cancer. The issue is that metastatic cells may be genetically different from the origin (founder) cells due to acquired ______ mutations.

Answer 3

mTOR

Somatic mutation